IMMX

Immix BiopharmaA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$15.00

+79.3% vs current

Most likely

Base case

45%

Probability

Target price

$9.50

+13.6% vs current

B-

Bear case

30%

Probability

Target price

$4.50

-46.2% vs current

AI sentiment snapshot

Latest data as of 2026-04-29

AI commentary

Primary-source evidence is solid for the key facts, but the quality gate classifies the memo as tentative because coverage is limited and evidence depth is thinner than a standard report. Deterministic signals remain near neutral, recent trusted-news support is absent in the packet, and the main reason to monitor the stock is the now-dated Q3 2026 readout after the March 30 enrollment-completion 8-K [#8-K-2026-03-30]. The 10-K also supports a less acute near-term cash concern, while still keeping medium-term financing risk in view [#10-K-2026-03-25].

RankAlpha Sentiment Codex - 2026-04-29

Open full AI memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-05-15catalystQ1 burn and runway disclosure should test cash-duration assumptionsHigh impact

The 2025 10-K said Immix had about $100.4 million of cash, cash equivalents and short-term investments at December 31, 2025, expected CIRM disbursements, and funding for at least 12 months from the filing date, but it also said additional capital will be needed beyond that period; the next quarterly filing is the nearest hard checkpoint for whether burn, grant receipts, and financing risk stay on plan [#10-K-2026-03-25].

2026-09-15eventNEXICART-2 topline results are expected in Q3 2026High impact

Immix disclosed in its March 30, 2026 8-K that enrollment for the NEXICART-2 clinical trial of NXC-201 is complete and that topline results are expected in Q3 2026, making this the clearest near-term valuation inflection for the stock [#8-K-2026-03-30].

2026-12-15catalystPost-readout financing or partnering path could reset the 2027 outlookHigh impact

The 10-K says current liquidity should fund planned operations for 12 months from the filing date but that additional capital will be needed beyond that window, so any credible post-data financing, collaboration, or regulatory-path update would matter for valuation only if the Q3 2026 readout is supportive [#10-K-2026-03-25].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-29 • Updated nightlySource: Internal modelMethodology